Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Santos M, Lanillos J, Lopez C, Alonso Gordoa T, Benavent M,
Keywords: pancreatic, neuroendocrine, mutations, correlation,
Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Vandamme T
Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,
Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,
#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Grabowski P
Authors: Lelek S, Sedding D, Benecke J, Siegmund B, Schrader J,
Keywords: Bronchopulmonary neuroendocrine tumors (BP-NET), somatostatin analogues, Lanreotide, signaling,
Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Schrader J
Authors: Weissmann V, Benten D, Fahl M, Eggers C, Izbicki J,
Keywords: targeted therapies, mTOR,